March 12, 2026 01:29 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Supreme Court allows first-ever passive euthanasia for 32-year-old man in coma for 13 years | As Iran-US war disrupts global gas supply, India issues guidelines to manage shortages | LPG crisis hits metros: Commercial cylinder shortage triggers panic as govt prioritises domestic supply | Iran war disrupts LPG supplies, restaurants in major Indian cities edge towards shutdown | ‘How dare you question judicial officers?’: SC raps Bengal SIR pleas, orders appellate tribunals for voter list appeals | 'Book withdrawn': NCERT apologises for controversial judiciary chapter after Supreme Court ban | Indian stock market surges as Brent crude dips below $100 after Trump’s Iran remarks | Australia grants asylum to five Iranian women footballers after anthem protest; Albanese says ‘they are safe here’ | Trump administration labels Afghanistan ‘state sponsor of wrongful detention’ | Trump threatens Iran with ‘20 times harder’ strike if oil flow through Strait of Hormuz is disrupted
Japan I Covid19
Image Cr: Unsplash

Japan approves home-made Covid-19 cure for emergency use

| @indiablooms | Nov 24, 2022, at 06:44 pm

Tokyo/UNI: The Japanese Health Ministry has authorised the island nation's first locally made COVID-19 oral treatment, Xocova, for emergency use.

This emergency approval was granted on the anticipated efficacy of Xocova and the acceptability of its safety profile based on the results obtained through the Phase 2 part (497 cases including the Phase 2a and Phase 2b parts combined) and the Phase 3 part (1,821 cases) of the Phase 2/3 study.

The pill was developed by Osaka-based pharmaceutical firm Shionogi & Co to treat coronavirus patients after they develop initial symptoms, such as fever, cough, a sore throat, a runny nose, and fatigue.

Xocova is an oral antiviral agent administered once daily for five days that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

It has been proven the most effective when administered during the first three days of symptoms starting.

The drug is known to reduce the viral load to three percent when taken on day four, and is not recommended for use during pregnancy.

Shionogi had filed for manufacturing and sales approval on Feb. 25, 2020.

The company said it had enough pills to treat one million people, and the drug will hit the shelves in Dec.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.